Stories about Medizinische Behandlung

Europäischer Rechnungshof - European Court of Auditors

(Pressebriefing) Kan EU afhjælpe kritiske mangler på lægemidler?

Kan EU afhjælpe kritiske mangler på lægemidler? - Online pressebriefing: onsdag den 17. september kl. 10.00 CEST - Offentliggørelse: samme dag kl. 17.00 CEST Den Europæiske Revisionsret inviterer til online pressebriefing vedrørende sin kommende særberetning om EU's foranstaltninger til at sikre tilgængelighed af lægemidler ...

Servier

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...

UCB

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...

STADA Arzneimittel AG

Press release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...

GEA Group Aktiengesellschaft

GEA expands portfolio for water and wastewater treatment – Flocmix solutions strengthen smart environmental technology

Helmholtz Munich

Therapeutic Vaccine for Chronic Hepatitis B Enters First Clinical Trial in Patients

PNO Innovation GmbH

TherVacB: Advance Curative Strategy for Chronic Hepatitis B

Helmholtz Munich

2

New Label-Free Imaging Tracks Cancer Treatment in Single Cells

Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...

Axolt

Axolt Launches Brain Supplement to Combat Post-Pandemic Burnout Crisis

Fraunhofer-Institut für Produktionstechnologie IPT

Transforming personalized medicine with AI-driven CAR-T manufacturing: Automated CAR-T cell production platform is ready for production

Intuitive Surgical Deutschland GmbH

Intuitive’s da Vinci 5 Surgical System Receives CE Mark / Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures

MedHub; Terumo

MedHub-AI and Terumo partner to market AI-based FFR in Japan

Tel Aviv, Israel (ots/PRNewswire) - MedHub-AI, pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical ...

Innovative Molecules GmbH

Innovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250

Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...

BIAL SA

BIAL Announces Oral Presentation at GBA1 Meeting 2025

Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...

Grünenthal Group

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...

Isotopia Molecular Imaging

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

Petach Tikva, Israel (ots/PRNewswire) - ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential ...

Isotopia Molecular Imaging

Isotopia and Cardirad Announce Launch of Isoprotrace® in Sweden and Denmark, Expanding Access to Advanced Prostate Cancer Imaging

Petah Tikva, Israel (ots/PRNewswire) - Isotopia Molecular Imaging, in partnership with Cardirad , proudly announces the launch of Isoprotrace®—an advanced Gallium-68 Gozetotide preparation kit for prostate cancer imaging—in Sweden and Denmark. The introduction of Isoprotrace® into these Nordic markets marks a ...

NeutroFlow

NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response

Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...

Johnson & Johnson MedTech

Personalized Treatment Plans Influence European Public's Willingness to Share Health Data

Leeds, England (ots/PRNewswire) - A global survey reveals Europe's growing confidence in the use of data and technology to transform healthcare and surgery. A global survey from Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, reveals that Europeans are favorable to sharing their health data in exchange for ...

Acousia Therapeutics GmbH

Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study

Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...

Helmholtz Munich

Engineering Smart Delivery for Gene Editors

Immunity Pharma

Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...

PNO Innovation GmbH

SGLT2 HYPE: New EU-funded Project Aims to Transform Hypertension Treatment